GGrantIndex
Sort

82,697 grants matching vaccine development

Application Of Mass Spectrometry To Structural Biology

$740,180
Kenneth Tomer · National Institute Of Environmental Health Sciences · ZIA · FY2011 · ES

Multiplex Serodiagnostic Protein Microarray

$740,101
Philip Louis Felgner · University Of California-Irvine · U01 · FY2011 · AI

PET Probes Targeting Immune Cells for Imaging Tuberculosis

$740,094
Carolyn J Anderson · University Of Pittsburgh At Pittsburgh · R01 · FY2015 · AI

Administrative Core

$740,051
David B. Weiner · Wistar Institute · U19 · FY2024 · AI

The Impact of Pre-exisiting SIV on Host Immunity to M tuberculosis in Macaques

$740,051
Charles A. Scanga · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · AI

Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine

$740,027
Thomas William Geisbert · University Of Texas Med Br Galveston · R01 · FY2022 · AI

Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine

$740,024
Thomas William Geisbert · University Of Texas Med Br Galveston · R01 · FY2024 · AI

Spatial Multi-omic Analysis of HIV-infected Cell Reservoirs in the Tumor Microenvironment

$740,000
Eli Boritz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI

Delivery of Biological Therapeutics: Using Engineered Particles and Novel Deliver

$740,000
Joseph M Desimone · Univ Of North Carolina Chapel Hill · DP1 · FY2009 · OD

Delivery of Biological Therapeutics: Using Engineered Particles and Novel Deliver

$740,000
Joseph M Desimone · Univ Of North Carolina Chapel Hill · DP1 · FY2010 · OD

SCC-IRG JST: PanCommunity: Leveraging Data and Models for Understanding and Improving Community Response in Pandemics

$739,996
Kasim S Candan · Arizona State University · · FY2021 · CSE

Effective CMV-based SIV vaccine regimens for newborn infants via IL-10 modulation

$739,979
Dennis J Hartigan-O'Connor · University Of California At Davis · R01 · FY2023 · AI

Engineered, multispecific antibodies as broad anti-filovirus therapeutics

$739,975
Jonathan R. Lai · Albert Einstein College Of Medicine · R01 · FY2020 · AI

In vivo modeling of IgH-reprogrammed B cells in non-human primates

$739,945
Chester J. Joyner · Scripps Research Institute, The · P01 · FY2025 · HL

HIV Neutralizing Antibodies: Isolation, characterization, and interaction with viral variants

$739,943
Nicole Doria-Rose · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI

Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine

$739,915
Thomas William Geisbert · University Of Texas Med Br Galveston · R01 · FY2023 · AI

Immunostimulatory DNA Priming of Lung Innate Immunity

$739,815
Dynavax Technologies Corporation · U01 · FY2003 · AI

Structural and functional definition of human astrovirus-receptor interactions

$739,788
Megan T Baldridge · Washington University · R01 · FY2024 · AI

Johns Hopkins University-Guangxi, China Clinical Trials Unit

$739,713
Jay B Jackson · Johns Hopkins University · UM1 · FY2012 · AI

Mechanisms of Chronic Hepatitis B Infection and Therapeutic Vaccines

$739,678
David R. Milich · Vaccine Research Institute Of San Diego · R01 · FY2007 · AI

Role of the microbiome in HIV vaccine induced heterogeneity

$739,661
James G. Kublin · Fred Hutchinson Cancer Research Center · R01 · FY2019 · AI

Glycosylation Mutants of Leishmania

$739,661
Stephen M Beverley · Washington University · R01 · FY2008 · AI

Investigating Interferon Antagonists in Delaying Innate Immune Responses to SARS-CoV-2

$739,638
Susan C. Baker · Loyola University Chicago · R01 · FY2024 · AI

Development of botulinum neurotoxin immunotherapy, serotypes C, D, F, and G

$739,630
James D. Marks · University Of California, San Francisco · U01 · FY2011 · AI

Broad spectrum inhibitors of paramyxovirus envelope proteins

$739,596
Anne Moscona · Columbia University Health Sciences · R01 · FY2025 · AI